A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease

Deferasirox is a once-daily, oral iron chelator developed for treating transfusional iron overload. Preclinical studies indicated that the kidney was a potential target organ of toxicity. As patients with sickle cell disease often have abnormal baseline renal function, the primary objective of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Vichinsky, Elliott, Onyekwere, Onyinye, Porter, John, Swerdlow, Paul, Eckman, James, Lane, Peter, Files, Beatrice, Hassell, Kathryn, Kelly, Patrick, Wilson, Felicia, Bernaudin, Françoise, Forni, Gian Luca, Okpala, Iheanyi, Ressayre-Djaffer, Catherine, Alberti, Daniele, Holland, Jaymes, Marks, Peter, Fung, Ellen, Fischer, Roland, Mueller, Brigitta U, Coates, Thomas
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2007
Materias:
Red Cells and Iron
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1974786/
https://www.ncbi.nlm.nih.gov/pubmed/17233848
http://dx.doi.org/10.1111/j.1365-2141.2006.06455.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1974786/
https://www.ncbi.nlm.nih.gov/pubmed/17233848
http://dx.doi.org/10.1111/j.1365-2141.2006.06455.x

Ejemplares similares